Aktieanalys

Remedy: Weak quarter due to milestone timing - Redeye

Redeye Publicerad: 26 Apr 2023 10:33

Redeye comment on Remedy’s Q1 business review. Sometimes milestone payments do not adapt to the quarterly economy so well, which is shown in the Q1-business review. Reported revenue during Q1 was EUR6.9m versus our estimated EUR11.1m. With a cost base largely fixed this resulted in an EBIT of EUR-5.6m in contrast to our expected EBIT of EUR-0.7m. The much anticipated Max Payne Remake has progressed into “proof of concept” stage during Q1. We believe our previous estimate of a H2 2025 release for this game is likely too conservative.

Länk till analysen i sin helhet: https://www.redeye.se/research/897394/remedy-weak-quarter-due-to-milestone-timing?utm_source=finwire&utm_medium=RSS

Nyheter om Remedy Entertainment

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!